(June 11 21:30) Forbes.com
The stock price of Alnylam Pharmaceuticals, a relatively smaller pharmaceutical company with a market capitalization of $18 billion, has seen a 22% rise over the last twenty-one trading days, and we believe the stock will likely continue to rally in the near term. The 22% rise can primarily be...
You can find the original article
here